<DOC>
	<DOCNO>NCT00474799</DOCNO>
	<brief_summary>The purpose study characterize repeat dose plasma profile , extent accumulation repeat dose pharmacokinetics morphine , morphine-3-glucuronide , morphine-6-glucuronide administration MNS075 two different , clinically-relevant dosing schedule .</brief_summary>
	<brief_title>Study Assess Safety , Tolerability Pharmacokinetic Profile MNS075 ( Intranasal Morphine )</brief_title>
	<detailed_description>This study open label , randomize , two-treatment , two-period , two-sequence , single-center , crossover study compare pharmacokinetics , safety tolerability MNS075 ( intranasal morphine ) dose 7.5 mg self-administered q1h 7 hour ( 8 dos ) 15 mg self-administered q3h 9 hour ( 4 dos ) .</detailed_description>
	<mesh_term>Morphine</mesh_term>
	<criteria>Healthy adult volunteer 18 year age old History alcohol , drug addiction , substance abuse . Known suspect currently abuse alcohol drug . Allergy hypersensitivity shellfish opioids . History seizure . Clinically significant structural functional abnormality nose upper airway , obstruction nasal passage , mucosal lesion nostril . Smoked used tobacco nicotine product past six month expect study . Positive hepatitis B hepatitis C HIV antibody .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2008</verification_date>
</DOC>